# Aoda Shengwu

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aoda-shengwu

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.aodashengwu.com
- Total disclosed funding: $4.2M
- Latest round: Series A (Aug 9, 2025)
- Investors on record: 1

## About

Founded in 2017 and based in Chengdu, China, Aoda Shengwu operates as a biopharmaceutical company that focuses on the research and development of targeted peptide drugs. It was recognized as the National High-tech Enterprise in 2021. The company has applied for more than 50 invention patents and has been authorized 14 invention patents. The company established a laboratory and established a research and development pipeline in 2018. In June 2024, Aoda Shengwu closed a strategic investment. In August 2025, Aoda Shengwu raised CNY 30 million of series A funding led by new investor Tao Capital.
Aoda Shengwu mainly engages in the research, development, production, and sales of targeted peptide drugs. It currently has 15 products, including drugs for type II diabetes, broad-spectrum coronavirus membrane fusion inhibitors, peptide vaccines for multiple myeloma, etc. Products can be used in the treatment of diabetes, coronavirus, and other diseases. The company generates revenue by selling targeted peptide drugs.

## Funding rounds

- Series A, Aug 9, 2025, $4.2M — Tao Capital

## Investors

- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A